SCHEMBL5366873

SCHEMBL5366873

Cn1n[c]cc(NS(C)(=O)=O)c1=O

nearest known ligand 0.34

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAPT P10636 1/20 0.34
KMT2A Q03164 1/20 0.34
BRD4 O60885 4/20 0.33
PKM P14618 1/20 0.33
KEAP1 Q14145 2/20 0.33
NFE2L2 Q16236 1/20 0.33
GLO1 Q04760 2/20 0.32
ALDH1A1 P00352 1/20 0.32
ALOX15 P16050 1/20 0.32
HTT P42858 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.32
PTGS1 P23219 2/20 0.31
PTGS2 P35354 2/20 0.31
JAK2 O60674 1/20 0.30
JAK1 P23458 1/20 0.30
EP300 Q09472 1/20 0.30
KAT2B Q92831 1/20 0.30
KAT8 Q9H7Z6 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5353939 0.78 KAT2B (0.42) MAPTBRD4PKMKAT2B
SCHEMBL5355440 0.68 KEAP1 (0.33) KMT2ABRD4KEAP1NFE2L2GLO1
SCHEMBL5360043 0.67 JAK2 (0.37) MAPTKEAP1NFE2L2GLO1ALOX15
SCHEMBL16446143 0.66 LMNA (0.32)
SCHEMBL18088733 0.62 NMT1 (0.54) KEAP1NFE2L2GLO1ALDH1A1PTGS1
SCHEMBL9450334 0.61 KEAP1 (0.42) KEAP1NFE2L2GLO1ALOX15HTT
SCHEMBL15243732 0.59 OXTR (0.63) KMT2AKEAP1ALDH1A1
SCHEMBL2210432 0.57 KEAP1 (0.38) BRD4KEAP1NFE2L2GLO1L3MBTL1
SCHEMBL2066412 0.57 KEAP1 (0.38) KEAP1NFE2L2GLO1ALOX15HTT
SCHEMBL2068498 0.57 KEAP1 (0.65) KMT2AKEAP1NFE2L2GLO1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1553096-B1 PYRAZOLE COMPOUNDS UBE INDUSTRIES (JP) 2012-10-31 EP disclosed
US-7294625-B2 Pyrazole compounds UBE INDUSTRIES, LTD. (JP) 2007-11-13 US disclosed
US-20060063934-A1 3-Pyridazonyl- or triazolopyridazinyl- 4-pyridinyl- or pyrimidinyl- pyrazoles, e.g., 4-(2-aminopyridin-4-yl)-3-phenyl-1-([1,2,4]triazolo[4,3-b]pyridazin-6-yl)-1H-pyrazole; p38MAP kinase inhibitors, used to treat rheumatoid arthritis UBE INDUSTRIES, LTD. (JP) 2006-03-23 US disclosed
EP-1553096-A1 PYRAZOLE COMPOUNDS Ube Industries, Ltd. (JP) 2005-07-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060063934-A1 3-Pyridazonyl- or triazolopyridazinyl- 4-pyridinyl- or pyrimidinyl- pyrazoles, e.g., 4-(2-aminopyridin-4-yl)-3-phenyl-1-([1,2,4]triazolo[4,3-b]pyridazin-6-yl)-1H-pyrazole; p38MAP kinase inhibitors, used to treat rheumatoid arthritis CNKSR1, MAPK1, MAPK3 MAPT 3650/4885KMT2A 1330/4885BRD4 202/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.